Heart stopping
Article Abstract:
Shield Diagnostics saw a rise in its share price following the announcement that its blood test was a more reliable way of forecasting heart attacks than were tests for cholesterol. The company then reported in Mar 1997 that blood samples had been mishandled, affecting US data. This led to a drop in Shield's share price. The price later rose after the company emphasised good results from the UK. Apax Ventures has sold a stake in the company, which could carry out a rights issue if no partner can be found for developing the blood test.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Shield's big deal
Article Abstract:
Shield Diagnostics started commercialization discussions for the company's test to predict heart attacks, called Activator Factor Twelve, in Feb 1997. A stock price rise followed, but the stock price subsequently dropped when no progress had been announced by Christmas 1997. The company has a small portfolio, and the failure to meet a deadline for a lead product has caused concern. The company could achieve an agreement, and the market would prefer it to be exclusive, which would mean bigger payments, but there is uncertainty.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Sum of the parts worth more than the whole
Article Abstract:
Alpha Omikron is an emerging markets trade and executive chairman Emmanuel Mastorakis must work to restore the company's fortunes, after shares collapsed from the 1995 introduction price. Alpha had planned to use cash flow from an established branded sports goods business to fund several start up ventures, including the distribution of paramedical products in Russia and the construction of a syringe factory in North Korea.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Yen warning. Chinks in the armour
- Abstracts: Credit Acceptance - CACC. Eisner's big Disney sale
- Abstracts: Top 10 b-to-b sites undergoing changes. Holding e-mail accountable. 'Upselling' strategies hit the Net: new tools allow targeting of customers for extra sales
- Abstracts: Call the market. Hanging on the telephone. Jardinerie Interiors set to bloom
- Abstracts: Aura Oslapas/IDEO. New look for an old face